Table 3.
Study | Interval portal vein embolization, % | Interval chemotherapy, % | Patients, n | Proportion of patients selected for stage 2, % | Liver resection, % | Major liver resection, % | R0 resection rate, % | Ablation, % | Postoperative morbidity, % | Postoperative mortality, % |
---|---|---|---|---|---|---|---|---|---|---|
Turrini et al.25 | 100 | 29 | 34 | 71 | 100 | 91 | 100 | 59 | 20 | 6 |
Tsim et al.26 | 95 | 13 | 33 | 87 | 100 | 85 | 58 | NR | 33 | 0 |
Narita et al.27 | 92 | 31 | 61 | 76 | 100 | 95 | NR | 8 | 54 | 0 |
Muratore et al.24 | 57 | 53 | 36 | 77 | 100 | 94 | 86 | 0 | 44 | 0 |
Brouquet et al.23 | 70 | 19 | 47 | 72 | 100 | 85 | 64 | 0 | 49 | 6 |
Bowers et al.22 | 72 | 15 | 32 | 82 | 84 | 59 | 52 | 7 | 56 | 4 |
Tsai et al.21 | 4 | 62 | 35 | 78 | 97 | 80 | NR | 20 | 26 | 6 |
Wicherts et al.20 | 20 | 78 | 41 | 69 | 100 | 76 | NR | 12 | 59 | 7 |
Pamecha et al.19 | 14 | 100 | 11 | 79 | 100 | 73 | 100 | 0 | 27 | 0 |
Tanaka et al.18 | 0 | 0 | 22 | 92 | 100 | 67 | 87 | 0 | 23 | 0 |
Total | 61 | 37 | 352 | 77 | 98 | 84 | 75 | 12 | 40 | 3 |
Range | 0–100 | 0–100 | 69–92 | 84–100 | 59–95 | 52–100 | 0–59 | 20–59 | 0–7 |
NR, not reported.